HanAll Biopharma, Achieving Net Income of 540M KRW to Turn into Surplus
HanAll Biopharma, Achieving Net Income of 540M KRW to Turn into Surplus
Hanall Biopharma, Completed the Clinical Trial Phase 1 of \'HL036\', New Medicine for Dry Eye Disease
Hanall Biopharma, Completed the Clinical Trial Phase 1 of \'HL036\', New Medicine for Dry Eye Diseas